Dr. Joseph McGuirk DO (Division Director, Hematologic Malignancies & Cellular Therapeutics; National CAR-T leader); Dr. Sunil Abhyankar MD (Prof, Dept. of Hematologic Malignancies; leads Midwest Stem Cell Therapy Center); Multiple BMT specialists
Leukemia, lymphoma (non-Hodgkin, large B-cell), multiple myeloma, ALL (acute lymphoblastic leukemia), blood cancers, sickle cell disease, hemophilia, autoimmune disorders, non-cancerous blood disorders
Autologous BMT, Allogeneic BMT, Haploidentical (half-matched) Transplant, Nonmyeloablative Transplant, Peripheral Blood Stem Cell Transplant, CAR-T Cell Therapy (all 7 FDA-approved: YESCARTA, KYMRIAH, ABECMA, BREYANZI, TECARTUS, CARVYKTI, AUCATZYL), CAR-NK Therapy (clinical trials), Photopheresis
Range: $$$$ (Insurance-covered for eligible diagnoses; clinical trials may reduce cost)
Covered by insurance for eligible cancer diagnoses. Among world's first CAR-T providers. Offers 20+ active CAR-T clinical trials which may reduce cost for eligible participants. First to administer Abecma (CAR-T for myeloma) in the world (2021).